Physician profile

Reginald Kai Mason

Surgery · Alton, IL

NPI 1699739607

$1,731.75

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$925.54
Food and Beverage$189.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $1,095.97 2024
Stryker Corporation $179.66 2019
Endogastric Solutions, INC $123.69 2020
Leica Microsystems INC. $98.90 2021
Covidien LP $88.08 2019-2020
Smith+Nephew, INC. $47.16 2019
Medtronic, INC. $37.91 2022-2024 Het
Braintree Laboratories, INC. $23.98 2020
Pacira Pharmaceuticals Incorporated $20.56 2020
Merck Sharp & Dohme LLC $15.84 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Reginald Kai Mason

$1,731.75

in general payments reported 2019-2025

Years
2019-2024
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/303646/reginald-kai-mason

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.